High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma

被引：31

作者：

Guo, Xiaofang ^{[1
,2
]}

Wang, Juan ^{[1
]}

Jin, Jietian ^{[3
]}

Chen, Hao ^{[4
]}

Zhen, Zijun ^{[1
]}

Jiang, Wenqi ^{[5
]}

Lin, Tongyu ^{[5
]}

Huang, Huiqiang ^{[5
]}

Xia, Zhongjun ^{[6
]}

Sun, Xiaofei ^{[1
]}

机构：

[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pediat Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 1, Eastern Hosp, Guangzhou, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Pathol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[4] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Clin Lab,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[5] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[6] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,State Key Lab Oncol South Chin, Guangzhou, Guangdong, Peoples R China

来源：

TRANSLATIONAL ONCOLOGY | 2018年 / 11卷 / 03期

关键词：

PD-L1; EXPRESSION; CANCER; NIVOLUMAB; MICROENVIRONMENT; IMMUNOTHERAPY; CELL-DEATH-1; CARCINOMA;

D O I：

10.1016/j.tranon.2018.03.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Blockade of the programmed cell death 1-programmed cell death ligand 1 pathway is a new and promising therapeutic approach in Hodgkin lymphoma (HL). To our knowledge, the impact of soluble programmed cell death ligand 1 (sPD-L1) serum levels on HL patient prognosis has not yet been investigated. In this study, the prognostic value of sPD-L1 was assessed in patients with HL. We measured serum sPD-L1 levels and identified their prognostic value in 108 newly diagnosed HL patients using an enzyme-linked immunosorbent assay (ELISA). We found higher serum sPD-L1 concentrations in HL patients than in healthy controls. The best sPD-L1 cutoff value for predicting disease progression risk was 25.1674 ng/ml. The 4-year progression-free survival (PFS) rates for the high-sPD-L1 and low-sPD-L1 groups were 78.8% and 93.3%, respectively. Multivariate survival analysis showed that advanced stage and higher sPD-L1 levels (>25.1674 ng/ml) were independent prognostic factors for shorter PFS. In addition, higher sPD-L1 levels were positively correlated with advanced stage and negatively correlated with peripheral blood monocyte number. The serum sPD-L1 level is an independent prognostic factor for PFS in HL patients and may allow identification of a subgroup of patients who require more intensive therapy and who may benefit from anti-PD-1 agents.

引用

页码：779 / 785

页数：7

共 64 条

[1]

Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy [J].